Gentian Diagnostics AS (OSL:GENT) EBIT per Share : kr1.43 (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Gentian Diagnostics AS EBIT per Share?

Gentian Diagnostics AS's EBIT per Share for the three months ended in Dec. 2024 was kr0.53. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was kr1.43.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Gentian Diagnostics AS's EBIT per Share or its related term are showing as below:

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Gentian Diagnostics AS was 16.90% per year. The lowest was -124.00% per year. And the median was -13.40% per year.

OSL:GENT's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 6.2
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Gentian Diagnostics AS's EBIT for the three months ended in Dec. 2024 was kr8.3 Mil.

Gentian Diagnostics AS EBIT per Share Historical Data

The historical data trend for Gentian Diagnostics AS's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gentian Diagnostics AS EBIT per Share Chart

Gentian Diagnostics AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-1.13

-1.52

-1.45

-0.62

1.32

Gentian Diagnostics AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.57	0.30	0.35	0.26	0.53

Gentian Diagnostics AS EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Gentian Diagnostics AS's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	20.721	/	15.762
=	1.31

Gentian Diagnostics AS's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	8.301	/	15.762
=	0.53

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.43

Gentian Diagnostics AS (OSL:GENT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Gentian Diagnostics AS EBIT per Share Related Terms

Thank you for viewing the detailed overview of Gentian Diagnostics AS's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Gentian Diagnostics AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gentian Diagnostics AS (OSL:GENT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bjornasveien 5, Moss, NOR, 1596

Website

https://www.gentian.com

Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.